Immunology

CAVR免疫学核心的总体目标是提供一个集中的资源来分析SIV-和 新城疫病毒特异性体液免疫应答在血清和粘膜标本中的检测及标准化 将由个别实验室进行的流式细胞仪分析的性能。一个全面的 将提供一系列标准化和定量的体液免疫分析，包括一个小组 测定中和抗体应答的补充试验和一种新开发的 提供ADCC活性的灵敏和可重复性的测定。以确保一致性 多色流式细胞术数据的产生和细胞免疫的分析，免疫学 CORE将协调以下方面的共识标准操作协议(SOP)的生成 免疫表型和细胞因子流式细胞术(CFC)检测，并监督实施和 对每个地点的每个SOP进行验证。具体目标包括：1.为 用酶联免疫吸附试验和SIV/SIV中和试验分析血清中的SIV/SHlV特异性抗体 为分析阴道和直肠中SIV和SIV特异性抗体反应提供集中资源 分泌物；以及3.确保不同组织进行的免疫表型和ICS分析标准化 通过制定协商一致的协议、实施能力测试以及 流式细胞仪数据分析的对比评价。这些活动将提供一个全面和 对这些疫苗方法引起的宿主免疫反应的稳健评估，将有助于确定 能够阻断慢病毒粘膜传播的反应。

The overall goals of the CAVR Immunology Core are to provide a centralized resource for analysis of SIV- and SHIV-specific humoral immune responses in serum and mucosal specimens and to standardize the performance of flow cytometric assays that will be carried out by individual laboratories. A comprehensive range of well-standardized and quantitative assays of humoral immunity will be offerered, including a panel of complementary assays for the determination of neutralizing antibody responses and a newly developed assay that provides sensitive and reproducible determination of ADCC activity. To ensure consistent generation of polychromatic flow cytometry data and assays of cell-mediated immunity, the Immunology Core will coordinate the generation of consensus standard operating protocols (SOPs) for immunophenotyping and cytokine flow cytometry (CFC) assays, and supervise the implementation and validation of each SOP at each location. Specific Aims include: 1. To provide a centralized resource for the analysis of SIV/SHlV-specific antibodies in sera using ELISA and SIV/SHIV neutralization assays; 2. To provide a centralized resource for analysis of SIV and SHIV-specific antibody responses in vaginal and rectal secretions; and 3. To ensure standardization of immunophenotyping and ICS assays conducted by different sites through the development of consensus protocols, implementation of proficiency testing, and comparative evaluation of flow cytometric data analysis. These activities will provide a comprehensive and robust assessment of host immune responses elicited by these vaccine approaches and will help define responses that are able to interrupt mucosal transmission of lentiviruses.